TEST BANK FOR CLAYTON’S BASIC PHARMACOLOGY FOR
NURSES 19TH EDITIONBY MICHELLE J. WILLIHNGANZ,
SAMUEL L. GUREVITZ, BRUCE CLAYTON COMPLETE
,Chapter n301: n3Drug n3Definitions, n3Standards, n3and n3Information n3Sources
n3Willihnganz: n3Clayton’s n3Basic n3Pharmacology n3 for n3Nurses, n319th n3Edition
MULTIPLE
n3CHOICE
1. Which n3name n3identifies n3a n3drug n3listed n3by n3the n3US
n3 Food n3andn3Drug n3Administration n3(FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS: n3 C
The n3official n3name n3is n3the n 3 name n3under n3which n3a n3drug
n3is n3listed n3by n3the n3FDA. n3The n3brand n3name, n3or
n3trademark, n3is n3the n3name n3given n3to n3a n3drug n3by n3its
n3manufacturer. n3The n3nonproprietary, n3or n3generic, n3name
n3is n3provided n3by n3the n3United n3States n3Adopted n3Names
DIF: Cognitive n3Level: n3Knowledge
n3Council. REF: n 3 p. n39
OBJ: n31NAT: n3NCLEX n3Client n3Needs n3Category: n3Safe,
n3Effective n3Caren3Environment n3TOP: n 3 Nursing n3Process n3Step:
n3Assessment CON:
n3Patient n3Education
2. Which n3source n3contains n3information n3specific n3to n3nutritional n3supplements?
a. USP n3Dictionary n3of n3USAN n3 &n3International n3Drug n3Names
b. Natural n3Medicines n3Comprehensive n3Database
c. United n3States n3Pharmacopoeia/National n3Formulary n3(USP n3NF)
d. Drug n3Interaction n3Facts
ANS: n3 C
United n3States n3Pharmacopoeia/National n3Formulary n3contains n3information n3specific n3to
n3nutritionaln3supplements. n3USP n3Dictionary n3of n3USAN n3& n3International n3Drug n3Names n3is
n3a n3compilation n3of n3drugn3names, n3pronunciation n3guide, n3and n3possible n3future n3FDA
n3approved n3drugs; n3it n3does n3not n3include n3nutritional n3supplements. n3 Natural n3Medicines
n3Comprehensive n3Database n3contains
evidence-based n3information n3on n3herbal n3medicines n3and n3herbal n3combination n3products; n3it
n3does n3notn3include n3information n3specific n3to n3nutritional n3supplements. n3Drug n3Interaction
n3Facts n3contains n3comprehensive n3information n3on n3drug n3 interaction n3facts; n3it n3 does n3not
n3 include n3nutritional n3supplements.
DIF: Cognitive n3Level: n3Knowledge REF: n 3 p. n34 OBJ:
n33n3NAT: n 3 NCLEX n3Client n3Needs n3 Category: n3Physiological n3Integrity
TOP: n 3 Nursing n3Process n3Step: n3Assessment CON: n 3 Nutrition n3| n3Patient n3Education
3. Which n3drug n3reference n3contains n3drug n3monographs n3that n3describe n3all n3drugs n3in n3a n3therapeutic
class?
n3
a. Drug n3Facts n3and n3Comparisons
,Test n3Bank n3For n3Clayton’s n3Basic n3Pharmacology n3for n3Nurses 3
n319th n3Edition
b. Drug n3Interaction n3Facts
c. Handbook n3on n3Injectable n3Drugs
d. Martindale—The n3Complete n3Drug n3Reference
ANS: n3 A
Drug n3Facts n3and n3Comparisons n3contains n3drug n3monographs n3that n3describe n3all
n3drugs n3in n3an3therapeutic n3class. n3Monographs n3are n3formatted n3as n3tables n3to n3allow
n3comparison n3of n3similarn3products, n3brand n3names, n3manufacturers, n3cost n3indices,
n3and n3available n3dosage n3forms n3Online n3version n3is n3available.
DIF: Cognitive n3Level: n3Knowledge REF: n 3 p. n34 n3Table n31.2
OBJ: n3 n3 n 3 3 NAT: n 3 NCLEX n3Client n3Needs n3Category: n3Physiological n3Integrity
TOP: n 3 Nursing n3Process n3Step: n3Assessment CON: n 3 Safety n3| n3Patient n3Education n3| n3Clinical
n3Judgment
4. Which n3drug n3reference n3contains n3monographs n3about n3 virtually n3every n3single-entityn3drug
availablen3in n3the n3United n3States n3and n3describes n3therapeutic n3uses n3of n3drugs, n3including
n3
approved n3and n3unapproved n3uses?
n3
a. Martindale: n3The n3Complete n3Drug n3Reference
b. AHFS n3Drug n3Information
c. Drug n3Reference
d. Drug n3Facts n3and n3Comparisons
ANS: n3 B
AHFS n3Drug n3Information n3contains n3monographs n3about n3virtually n3every n3single-entity
n3drug n3available n3in n3the n3United n3States n3and n3describes n3therapeutic n3uses n3of n3drugs,
n3 including n3approved n3andn3unapproved n3uses.
DIF: Cognitive n3Level: n3Knowledge REF: n 3 p. n34 n3Table n31.2
OBJ: n3 n3 n 3 3 NAT: n 3 NCLEX n3Client n3Needs n3Category: n3Physiological n3Integrity
TOP: n 3 Nursing n3Process n3Step: n3Planning CON: n 3 Safety n3| n3Patient n3Education n3| n3Clinical n3Judgment
5. Which n3online n3drug n3reference n3makes n3available n3to n3healthcare n3providers n3and n3the
public n3a n3standard, n3comprehensive, n3up-to-date n3look n3up n3and n3downloadable n3resource
n3
about n3medicines?
n3
a. American n3Drug n3Index
b. American n3Hospital n3Formulary
c. DailyMed
d. Drug n3Reference
ANS: n3 C
DailyMed n3makes n3available n3to n3healthcare n3providers n3and n3the n3public n3a n3standard,
n3comprehensive,n3up-to-date n3look n3up n3and n3downloadable n3resource n3about n3medicines. n3The
n3American n3Drug n3Index n3isn3not n3appropriate n3for n3patient n3use. n3The n3American n3Hospital
n3Formulary n3is n3not n3appropriate n3for n3patient n3 use. n3The n3drug n3reference n3 is n3 not
n3 appropriate n3for n3patient n3 use.
DIF: Cognitive n3Level: n3Knowledge REF: n 3 p. n33 n3| n3p. n34
OBJ: n33n3NAT: n 3 NCLEX n3Client n3Needs n3Category:
n3Physiological n3Integrity
TOP: n 3 Nursing n3Process n3Step: n3Implementation
CON: n 3 Safety n3| n3Patient n3Education n3| n3Clinical n3Judgment
6. Which n3legislation n3authorizes n3the n3FDA n3to n3determine n3the n3safetyn3of n3a n3drug n3before n3its
marketing?
n3
a. Federal n3Food, n3Drug, n3and n3Cosmetic n3Act n3(1938)
b. Durham n3Humphrey n3Amendment n3(1952)
, Test n3Bank n3For n3Clayton’s n3Basic n3Pharmacology n3for n3Nurses 4
n319th n3Edition
c. Controlled n3Substances n3Act n3(1970)
d. Kefauver n3Harris n3Drug n3Amendment n3(1962)
ANS: n3 A
The n3Federal n3Food, n3Drug, n3and n3Cosmetic n3Act n3of n31938 n3authorized n3the n3FDA n3to
n3determine n3the n3safety n3of n3all n3drugs n3before n3marketing. n3Later n3amendments n3and n3acts
n3helped n3tighten n3FDA n3control n3and n3ensure n3drug n3safety. n3The n3Durham n3Humphrey
n3Amendment n3defines n3the n3kinds n3of n3drugs n3that n3cannot n3be n3used n3safely n3without
n3medical n3supervision n3and n3restricts n3their n3sale n3to n3prescription n3by n3a n3licensed
n3practitioner. n3The n3Controlled n3Substances n3Act n3addresses n3only n3controlled n3substances
n3andn3their n3categorization. n3The n3Kefauver n3Harris n3Drug n3Amendment n3ensures n3drug
n3efficacy n3and n3greatern3drug n3safety. n3Drug n3manufacturers n3are n3required n3to n3prove n3to n3the
n3FDA n3the n3effectiveness n3of n3their n3products n3before n3marketing n3them.
DIF: Cognitive n3Level: n3Knowledge REF: n3p. n3 5 n3Table n3l.3
OBJ: n 3 5 NAT: n3NCLEX n3Client n3Needs n3Category: n3Physiological
n3Integrityn3TOP: n 3 Nursing n3Process n3 Step: n3Assessment
CON: n 3 Safety n3| n3Patient n3Education n3| n3Evidence n3| n3Health n3Care n3Law
7. Which n3classification n3does n3meperidine n3(Demerol) n3fall n3under?
a. I
b. II
c. III
d. IV
ANS: n3 B
Meperidine n3(Demerol) n3is n3a n3Schedule n3II n3drug; n3it n3has n3a n3high n3potential n3for n3abuse
n3and n3may n3lead n3ton3severe n3psychological n3and n3physical n3dependence. n3Schedule n3I n3drugs
n3have n3high n3potential n3for n3abusen3and n3no n3recognized n3medical n3use. n3Schedule n3III n3drugs
n3have n3some n3potential n3for n3abuse. n3Use n3may n3lead n3to n3low n3to n3moderate n3physical
n3dependence n3or n3high n3psychological n3dependence. n3Schedule n3IV n3drugs n3have n3low
n3potential n3for n3abuse. n3Use n3may n3lead n3to n3limited n3physical n3or n3psychological
n3dependence.
DIF: Cognitive n3Level: n3Knowledge REF: n 3 p. n310 OBJ:
n32n3NAT: n 3 NCLEX n3Client n3Needs n3Category: n3Safe, n3Effective n3Care
n3Environment
TOP: n 3 Nursing n3Process n3Step: n3Assessment CON: n 3 Patient n3Education n3| n3Addiction n3| n3Pain
8. Which n3action n3would n3the n3FDA n3take n3to n3expedite n3drug n3development n3 and n3approval n3for
an n3outbreakn3of n3smallpox?
n3
a. List n3smallpox n3as n3a n3health n3orphan n3disease.
b. Omit n3the n3preclinical n3research n3phase.
c. Extend n3the n3clinical n3research n3phase.
d. Fast n3track n3the n3investigational n3drug.
ANS: n3 D
Once n3the n3Investigational n3New n3Drug n3Application n3has n3been n3approved, n3the n3drug n3can
n3receive n3highest n3priority n3within n3the n3agency, n3which n3is n3called n3fast n3tracking. n3A
n3smallpox n3outbreak n3would n3become n3a n3priority n3concern n3in n3the n3world. n3Orphan
n3diseases n3are n3not n3researched n3in n3a n3priority n3manner. n3Preclinical n3research n3is n3not
n3omitted. n3Extending n3any n3phase n3of n3the n3research n3would n3meann3a n3longer n3time n3to
n3develop n3a n3vaccine. n3The n3FDA n3must n3ensure n3that n3all n3phases n3of n3the n3preclinical n3and
n3clinical n3research n3phase n3 have n3 been n3completed n3 in n3a n3safe n3manner.
DIF: Cognitive n3Level: n3Knowledge REF: n3 n3 n3p. n37 OBJ: n 3 5
NURSES 19TH EDITIONBY MICHELLE J. WILLIHNGANZ,
SAMUEL L. GUREVITZ, BRUCE CLAYTON COMPLETE
,Chapter n301: n3Drug n3Definitions, n3Standards, n3and n3Information n3Sources
n3Willihnganz: n3Clayton’s n3Basic n3Pharmacology n3 for n3Nurses, n319th n3Edition
MULTIPLE
n3CHOICE
1. Which n3name n3identifies n3a n3drug n3listed n3by n3the n3US
n3 Food n3andn3Drug n3Administration n3(FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS: n3 C
The n3official n3name n3is n3the n 3 name n3under n3which n3a n3drug
n3is n3listed n3by n3the n3FDA. n3The n3brand n3name, n3or
n3trademark, n3is n3the n3name n3given n3to n3a n3drug n3by n3its
n3manufacturer. n3The n3nonproprietary, n3or n3generic, n3name
n3is n3provided n3by n3the n3United n3States n3Adopted n3Names
DIF: Cognitive n3Level: n3Knowledge
n3Council. REF: n 3 p. n39
OBJ: n31NAT: n3NCLEX n3Client n3Needs n3Category: n3Safe,
n3Effective n3Caren3Environment n3TOP: n 3 Nursing n3Process n3Step:
n3Assessment CON:
n3Patient n3Education
2. Which n3source n3contains n3information n3specific n3to n3nutritional n3supplements?
a. USP n3Dictionary n3of n3USAN n3 &n3International n3Drug n3Names
b. Natural n3Medicines n3Comprehensive n3Database
c. United n3States n3Pharmacopoeia/National n3Formulary n3(USP n3NF)
d. Drug n3Interaction n3Facts
ANS: n3 C
United n3States n3Pharmacopoeia/National n3Formulary n3contains n3information n3specific n3to
n3nutritionaln3supplements. n3USP n3Dictionary n3of n3USAN n3& n3International n3Drug n3Names n3is
n3a n3compilation n3of n3drugn3names, n3pronunciation n3guide, n3and n3possible n3future n3FDA
n3approved n3drugs; n3it n3does n3not n3include n3nutritional n3supplements. n3 Natural n3Medicines
n3Comprehensive n3Database n3contains
evidence-based n3information n3on n3herbal n3medicines n3and n3herbal n3combination n3products; n3it
n3does n3notn3include n3information n3specific n3to n3nutritional n3supplements. n3Drug n3Interaction
n3Facts n3contains n3comprehensive n3information n3on n3drug n3 interaction n3facts; n3it n3 does n3not
n3 include n3nutritional n3supplements.
DIF: Cognitive n3Level: n3Knowledge REF: n 3 p. n34 OBJ:
n33n3NAT: n 3 NCLEX n3Client n3Needs n3 Category: n3Physiological n3Integrity
TOP: n 3 Nursing n3Process n3Step: n3Assessment CON: n 3 Nutrition n3| n3Patient n3Education
3. Which n3drug n3reference n3contains n3drug n3monographs n3that n3describe n3all n3drugs n3in n3a n3therapeutic
class?
n3
a. Drug n3Facts n3and n3Comparisons
,Test n3Bank n3For n3Clayton’s n3Basic n3Pharmacology n3for n3Nurses 3
n319th n3Edition
b. Drug n3Interaction n3Facts
c. Handbook n3on n3Injectable n3Drugs
d. Martindale—The n3Complete n3Drug n3Reference
ANS: n3 A
Drug n3Facts n3and n3Comparisons n3contains n3drug n3monographs n3that n3describe n3all
n3drugs n3in n3an3therapeutic n3class. n3Monographs n3are n3formatted n3as n3tables n3to n3allow
n3comparison n3of n3similarn3products, n3brand n3names, n3manufacturers, n3cost n3indices,
n3and n3available n3dosage n3forms n3Online n3version n3is n3available.
DIF: Cognitive n3Level: n3Knowledge REF: n 3 p. n34 n3Table n31.2
OBJ: n3 n3 n 3 3 NAT: n 3 NCLEX n3Client n3Needs n3Category: n3Physiological n3Integrity
TOP: n 3 Nursing n3Process n3Step: n3Assessment CON: n 3 Safety n3| n3Patient n3Education n3| n3Clinical
n3Judgment
4. Which n3drug n3reference n3contains n3monographs n3about n3 virtually n3every n3single-entityn3drug
availablen3in n3the n3United n3States n3and n3describes n3therapeutic n3uses n3of n3drugs, n3including
n3
approved n3and n3unapproved n3uses?
n3
a. Martindale: n3The n3Complete n3Drug n3Reference
b. AHFS n3Drug n3Information
c. Drug n3Reference
d. Drug n3Facts n3and n3Comparisons
ANS: n3 B
AHFS n3Drug n3Information n3contains n3monographs n3about n3virtually n3every n3single-entity
n3drug n3available n3in n3the n3United n3States n3and n3describes n3therapeutic n3uses n3of n3drugs,
n3 including n3approved n3andn3unapproved n3uses.
DIF: Cognitive n3Level: n3Knowledge REF: n 3 p. n34 n3Table n31.2
OBJ: n3 n3 n 3 3 NAT: n 3 NCLEX n3Client n3Needs n3Category: n3Physiological n3Integrity
TOP: n 3 Nursing n3Process n3Step: n3Planning CON: n 3 Safety n3| n3Patient n3Education n3| n3Clinical n3Judgment
5. Which n3online n3drug n3reference n3makes n3available n3to n3healthcare n3providers n3and n3the
public n3a n3standard, n3comprehensive, n3up-to-date n3look n3up n3and n3downloadable n3resource
n3
about n3medicines?
n3
a. American n3Drug n3Index
b. American n3Hospital n3Formulary
c. DailyMed
d. Drug n3Reference
ANS: n3 C
DailyMed n3makes n3available n3to n3healthcare n3providers n3and n3the n3public n3a n3standard,
n3comprehensive,n3up-to-date n3look n3up n3and n3downloadable n3resource n3about n3medicines. n3The
n3American n3Drug n3Index n3isn3not n3appropriate n3for n3patient n3use. n3The n3American n3Hospital
n3Formulary n3is n3not n3appropriate n3for n3patient n3 use. n3The n3drug n3reference n3 is n3 not
n3 appropriate n3for n3patient n3 use.
DIF: Cognitive n3Level: n3Knowledge REF: n 3 p. n33 n3| n3p. n34
OBJ: n33n3NAT: n 3 NCLEX n3Client n3Needs n3Category:
n3Physiological n3Integrity
TOP: n 3 Nursing n3Process n3Step: n3Implementation
CON: n 3 Safety n3| n3Patient n3Education n3| n3Clinical n3Judgment
6. Which n3legislation n3authorizes n3the n3FDA n3to n3determine n3the n3safetyn3of n3a n3drug n3before n3its
marketing?
n3
a. Federal n3Food, n3Drug, n3and n3Cosmetic n3Act n3(1938)
b. Durham n3Humphrey n3Amendment n3(1952)
, Test n3Bank n3For n3Clayton’s n3Basic n3Pharmacology n3for n3Nurses 4
n319th n3Edition
c. Controlled n3Substances n3Act n3(1970)
d. Kefauver n3Harris n3Drug n3Amendment n3(1962)
ANS: n3 A
The n3Federal n3Food, n3Drug, n3and n3Cosmetic n3Act n3of n31938 n3authorized n3the n3FDA n3to
n3determine n3the n3safety n3of n3all n3drugs n3before n3marketing. n3Later n3amendments n3and n3acts
n3helped n3tighten n3FDA n3control n3and n3ensure n3drug n3safety. n3The n3Durham n3Humphrey
n3Amendment n3defines n3the n3kinds n3of n3drugs n3that n3cannot n3be n3used n3safely n3without
n3medical n3supervision n3and n3restricts n3their n3sale n3to n3prescription n3by n3a n3licensed
n3practitioner. n3The n3Controlled n3Substances n3Act n3addresses n3only n3controlled n3substances
n3andn3their n3categorization. n3The n3Kefauver n3Harris n3Drug n3Amendment n3ensures n3drug
n3efficacy n3and n3greatern3drug n3safety. n3Drug n3manufacturers n3are n3required n3to n3prove n3to n3the
n3FDA n3the n3effectiveness n3of n3their n3products n3before n3marketing n3them.
DIF: Cognitive n3Level: n3Knowledge REF: n3p. n3 5 n3Table n3l.3
OBJ: n 3 5 NAT: n3NCLEX n3Client n3Needs n3Category: n3Physiological
n3Integrityn3TOP: n 3 Nursing n3Process n3 Step: n3Assessment
CON: n 3 Safety n3| n3Patient n3Education n3| n3Evidence n3| n3Health n3Care n3Law
7. Which n3classification n3does n3meperidine n3(Demerol) n3fall n3under?
a. I
b. II
c. III
d. IV
ANS: n3 B
Meperidine n3(Demerol) n3is n3a n3Schedule n3II n3drug; n3it n3has n3a n3high n3potential n3for n3abuse
n3and n3may n3lead n3ton3severe n3psychological n3and n3physical n3dependence. n3Schedule n3I n3drugs
n3have n3high n3potential n3for n3abusen3and n3no n3recognized n3medical n3use. n3Schedule n3III n3drugs
n3have n3some n3potential n3for n3abuse. n3Use n3may n3lead n3to n3low n3to n3moderate n3physical
n3dependence n3or n3high n3psychological n3dependence. n3Schedule n3IV n3drugs n3have n3low
n3potential n3for n3abuse. n3Use n3may n3lead n3to n3limited n3physical n3or n3psychological
n3dependence.
DIF: Cognitive n3Level: n3Knowledge REF: n 3 p. n310 OBJ:
n32n3NAT: n 3 NCLEX n3Client n3Needs n3Category: n3Safe, n3Effective n3Care
n3Environment
TOP: n 3 Nursing n3Process n3Step: n3Assessment CON: n 3 Patient n3Education n3| n3Addiction n3| n3Pain
8. Which n3action n3would n3the n3FDA n3take n3to n3expedite n3drug n3development n3 and n3approval n3for
an n3outbreakn3of n3smallpox?
n3
a. List n3smallpox n3as n3a n3health n3orphan n3disease.
b. Omit n3the n3preclinical n3research n3phase.
c. Extend n3the n3clinical n3research n3phase.
d. Fast n3track n3the n3investigational n3drug.
ANS: n3 D
Once n3the n3Investigational n3New n3Drug n3Application n3has n3been n3approved, n3the n3drug n3can
n3receive n3highest n3priority n3within n3the n3agency, n3which n3is n3called n3fast n3tracking. n3A
n3smallpox n3outbreak n3would n3become n3a n3priority n3concern n3in n3the n3world. n3Orphan
n3diseases n3are n3not n3researched n3in n3a n3priority n3manner. n3Preclinical n3research n3is n3not
n3omitted. n3Extending n3any n3phase n3of n3the n3research n3would n3meann3a n3longer n3time n3to
n3develop n3a n3vaccine. n3The n3FDA n3must n3ensure n3that n3all n3phases n3of n3the n3preclinical n3and
n3clinical n3research n3phase n3 have n3 been n3completed n3 in n3a n3safe n3manner.
DIF: Cognitive n3Level: n3Knowledge REF: n3 n3 n3p. n37 OBJ: n 3 5
